ROCHE / ACCENTURE
to stay monolithic ,” adds Waelchli .
Accenture ’ s IPP is a fully cloud based solution , garnering access to a real-world data repository of over 50mn electronic medical records . The new platform will therefore grow in line with Roche Diabetes Care ’ s vision , and give the company the ability to scale quickly . “ This is one advantage which the IPP is bringing ,” says Waelchli . “ It is bringing scalability , because Roche Diabetes Care wants to support patients and caregivers 24-7 , which is going to be enabled through our cloud based provisioning .
“ Further , it is not only the patient who may need to access this information . This solutions also grants doctors greater and remote visibility so they can make more informed decisions and , as a result , consult better .”
“ Speed will matter ,” adds Beynon . “ Of course , when you pioneer things you need to be quick , which is why we chose Accenture , because we wish to be fast and scale quickly . I ’ m convinced that we are delivering the right thing for the patient and for society .
“ With Accenture , the company has the key enabler for the integration that we need immediately . We don ’ t need to build , we don ’ t need to buy , and it will completely enable our strategy of integrating , collecting and computing in this area .”
Technological delivery
Beynon continues : “ We want to create an open digital diabetes ecosystem , and become the largest leading digital ecosystem out there ,” Beynon says .
88 October 2017